Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | STK10 | O94804 | 2/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.68 |
| ▸ | RET | P07949 | 2/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.68 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.68 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | CSF1R | P07333 | 1/20 | 0.68 |
| ▸ | HCK | P08631 | 1/20 | 0.68 |
| ▸ | KIT | P10721 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 1/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020489 | 0.89 | KDR (0.81) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1226910 | 0.87 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227665 | 0.84 | KDR (0.77) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1226894 | 0.83 | KDR (0.83) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL14140810 | 0.83 | KDR (0.77) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227648 | 0.83 | KDR (0.75) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227548 | 0.83 | KDR (0.77) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL4281456 | 0.82 | KDR (0.71) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227552 | 0.82 | KDR (0.77) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL12899428 | 0.82 | KDR (0.79) | KDRCYP3A4FGFR1KCNH2STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393667-B2 | Stereoselective reduction process for the preparation of pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| US-20060286646-A1 | STEREOSELECTIVE REDUCTION PROCESS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060286646-A1 | STEREOSELECTIVE REDUCTION PROCESS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS | ADH1C, ADH5, ADH1A | KDR 4188/4885CYP3A4 76/4885FGFR1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.